Pharmaust Limited (AU:NUZ) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Neurizon Therapeutics Limited, a biotech firm focused on neurodegenerative disease treatments, has updated its Securities Trading Policy, as announced on the ASX. The company is actively advancing its lead drug candidate, NUZ-001, which targets ALS, the most prevalent form of motor neurone disease. This update aligns with Neurizon’s commitment to accelerating treatment access and exploring broader applications for its drug.
For further insights into AU:NUZ stock, check out TipRanks’ Stock Analysis page.